Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Solid Tumors, Non-small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07435038
What this trial is testing

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more
Betta Pharmaceuticals Co., Ltd. 120
Testing effectiveness (Phase 2)Ended earlyNCT00470548
What this trial is testing

Abraxane and Alimta in Advanced Solid Tumors

Who this might be right for
Breast CancerLung CancerUnspecified Adult Solid Tumor, Protocol Specific
University of California, Davis 49
Early research (Phase 1)Ended earlyNCT05397093
What this trial is testing

ITIL-306 in Advanced Solid Tumors

Who this might be right for
Epithelial Ovarian CancerNon-small Cell Lung CancerRenal Cell Carcinoma
Instil Bio 1
Early research (Phase 1)Study completedNCT04881045
What this trial is testing

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

Who this might be right for
Non-Small Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckOvarian Cancer
Pfizer 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT03157128
What this trial is testing

Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+1 more
Eli Lilly and Company 857
Early research (Phase 1)Study completedNCT01495663
What this trial is testing

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Who this might be right for
Cancer
Cellectar Biosciences, Inc. 12
Early research (Phase 1)Study completedNCT05858164
What this trial is testing

A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsNon-small Cell Lung Cancer
Bayer 45
Early research (Phase 1)Ended earlyNCT05061537
What this trial is testing

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Who this might be right for
Renal Cell CancerMelanomaNon-Small-Cell Lung Cancer+7 more
Pfizer 13
Testing effectiveness (Phase 2)Looking for participantsNCT04683250
What this trial is testing

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Who this might be right for
RET-altered Non Small Cell Lung CancerRET-altered Solid Tumors
Taiho Pharmaceutical Co., Ltd. 244
Early research (Phase 1)Active Not RecruitingNCT02988960
What this trial is testing

ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors Cancer
AbbVie 163
Early research (Phase 1)Study completedNCT00010023
What this trial is testing

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Cancer
NYU Langone Health
Early research (Phase 1)Looking for participantsNCT07361562
What this trial is testing

A Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+3 more
Cogent Biosciences, Inc. 100
Testing effectiveness (Phase 2)Looking for participantsNCT06747585
What this trial is testing

Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Who this might be right for
Squamous Non-small-cell Lung CancerHead and Neck Squamous Cell CarcinomaCervical Squamous Cell Carcinoma+1 more
Alentis Therapeutics AG 170
Early research (Phase 1)WithdrawnNCT05393635
What this trial is testing

ITIL-168 in Advanced Solid Tumors

Who this might be right for
Cervical CancerHead and Neck Squamous Cell CarcinomaNon-small Cell Lung Cancer
Instil Bio
Testing effectiveness (Phase 2)Looking for participantsNCT05985655
What this trial is testing

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 230
Early research (Phase 1)Study completedNCT00514306
What this trial is testing

Study of Intermittent OSI-906 Dosing

Who this might be right for
Advanced Solid Tumors
Astellas Pharma Inc 79
Early research (Phase 1)Ended earlyNCT05514717
What this trial is testing

XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Non-Small Cell Lung Cancer+3 more
Day One Biopharmaceuticals, Inc. 57
Testing effectiveness (Phase 2)Study completedNCT00452413
What this trial is testing

Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerMalignant Solid Tumor
Eli Lilly and Company 65
Testing effectiveness (Phase 2)Active Not RecruitingNCT04644068
What this trial is testing

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Who this might be right for
Ovarian CancerBreast CancerPancreatic Cancer+10 more
AstraZeneca 702
Testing effectiveness (Phase 2)Active Not RecruitingNCT04946968
What this trial is testing

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

Who this might be right for
Advanced Solid TumoursNon-small Cell Lung CancerHead and Neck Squamous Cell Carcinoma
National Cancer Centre, Singapore 24
Next Page